Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease
about
The Alzheimer's amyloid-degrading peptidase, neprilysin: can we control it?Calcium-Sensing Receptors of Human Neural Cells Play Crucial Roles in Alzheimer's DiseaseCathepsin B is a New Drug Target for Traumatic Brain Injury Therapeutics: Evidence for E64d as a Promising Lead Drug CandidateThe Possible Roles of the Dentate Granule Cell's Leptin and Other Ciliary Receptors in Alzheimer's NeuropathologyTransient dynamics of Aβ contribute to toxicity in Alzheimer's diseaseAlzheimer's disease--a panorama glimpseBrain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeuticPurification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid-β Variants and Structural Analysis by Solution NMR SpectroscopyStructural Analysis and Aggregation Propensity of Pyroglutamate Aβ(3-40) in Aqueous TrifluoroethanolFibrils of Truncated Pyroglutamyl-Modified Aβ Peptide Exhibit a Similar Structure as Wildtype Mature Aβ FibrilsNatural Products from Microalgae with Potential against Alzheimer's Disease: Sulfolipids Are Potent Glutaminyl Cyclase Inhibitors.Cortical pyroglutamate amyloid-β levels and cognitive decline in Alzheimer's disease.Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β.Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.The C-terminal threonine of Aβ43 nucleates toxic aggregation via structural and dynamical changes in monomers and protofibrils.Activity and architecture of pyroglutamate-modified amyloid-β (AβpE3-42) poresDisordered amyloidogenic peptides may insert into the membrane and assemble into common cyclic structural motifs.Role of the fast kinetics of pyroglutamate-modified amyloid-β oligomers in membrane binding and membrane permeability.Age-induced reduction of autophagy-related gene expression is associated with onset of Alzheimer's disease.Alzheimer's protective A2T mutation changes the conformational landscape of the Aβ₁₋₄₂ monomer differently than does the A2V mutation.Pyroglutamyl-N-terminal prion protein fragments in sheep brain following the development of transmissible spongiform encephalopathies.Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X.Pyroglutamate-Modified Amyloid-β(3-42) Shows α-Helical Intermediates before Amyloid Formation.Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains.Catalytically active tissue transglutaminase colocalises with Aβ pathology in Alzheimer's disease mouse models.Abundant pyroglutamate-modified ABri and ADan peptides in extracellular and vascular amyloid deposits in familial British and Danish dementias.N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits.Molecular characterization of tick salivary gland glutaminyl cyclase.Outstanding Phenotypic Differences in the Profile of Amyloid-β between Tg2576 and APPswe/PS1dE9 Transgenic Mouse Models of Alzheimer's Disease.Neuroprotective effect of arctigenin via upregulation of P-CREB in mouse primary neurons and human SH-SY5Y neuroblastoma cells.pGluAβ increases accumulation of Aβ in vivo and exacerbates its toxicity.N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody.Abundance of Aβ₅-x like immunoreactivity in transgenic 5XFAD, APP/PS1KI and 3xTG mice, sporadic and familial Alzheimer's disease.Deciphering the molecular profile of plaques, memory decline and neuron loss in two mouse models for Alzheimer's disease by deep sequencing.Alzheimer's disease Aβ assemblies mediating rapid disruption of synaptic plasticity and memory.Open questions for Alzheimer's disease immunotherapy.Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy.Posttranslational modification impact on the mechanism by which amyloid-β induces synaptic dysfunction.Preclinical to phase II amyloid beta (Aβ) peptide modulators under investigation for Alzheimer's disease.Hypothesis: glutaminyl cyclase inhibitors decrease risks of Alzheimer's disease and related dementias.
P2860
Q21296650-B7BFE83D-2765-4CB0-8807-B9B492D7BA1FQ26747527-2BC33F2F-3905-4B21-980E-B89297EC2B88Q26782938-BF4309E7-679E-40C8-A159-C5AD100EC595Q26799897-21CFC973-56F2-4CA0-9929-77BB3209F648Q26827421-30173EC4-23DC-4B54-9863-E2CA07426224Q27011749-6D62264C-6964-4461-919C-4BE454564D7FQ28235248-5709FC17-4415-44AA-9E1D-0BE156E4B3A2Q28550062-F4004710-9E7D-45A9-92FB-2A78DFEB3A6BQ28551142-DBBF220E-64A7-4D50-825C-26AFAA10C052Q28829500-BD31E521-9A2B-4A05-9010-A8B953A7D8EDQ30313757-73461254-C0D4-4609-9626-283733BFFB45Q30361851-67C60D65-2F88-48B6-9729-93E4F5403B4FQ30423789-8AB2FC07-9D26-44A4-AFF7-D4CEDB4FE1DDQ30512697-B684DA31-0A68-452E-914F-8974EA743173Q33649356-4B0E8286-30F8-41E6-B8A5-ABB1E2A3812FQ33894606-E85D62C1-C81E-48D5-BE4A-9E2D46BEF655Q34084687-42BD308D-77BD-40A9-93CD-01806C69856CQ34434154-B68C69DF-082A-4E9D-A26E-29182AB6FD06Q34987490-9FE51A05-29C8-4A0C-9C63-0FB82032FFFEQ35050571-04F59D40-569A-42D2-93E5-03F57972DDD4Q35600113-C7D2700D-FDCE-4E8C-BD6E-2EA72DCFFC22Q36340365-B148042E-F718-401E-B616-2EB4202FD5F9Q36356545-CCDE97B4-7CA4-4222-8629-0FD0FC5A3B05Q36424815-9D2DD0C7-B6A0-4BE9-AFD1-967A6A1B4A95Q36536417-5475D97F-09CA-43D5-9998-701298633C68Q36605288-749884C6-F09A-4DB2-86F3-FD41E6B2F2E7Q37043304-3304A81F-E142-4588-8A5B-472D429EE432Q37086364-DAF1D204-F90E-4B75-BD34-367F0D640551Q37169151-6F330FB6-1693-4E83-A937-1C37AE135017Q37225208-550DDE25-280A-4AB2-8B6C-F7D000F26989Q37322106-A5D7F480-5C92-4125-A541-9005C9F6FFA1Q37485472-75EFBE92-EEFC-4E0D-A36B-BD4A1820B064Q37684387-3F9BCCC3-5033-4E4C-B7D8-991EBD94526AQ37718997-A2349120-F18B-4F84-BAF4-9460E7EF8117Q38026984-44C4728F-5E4A-40E8-B480-75069ECB34A0Q38176097-62506ABD-82A0-47D3-A030-0D7A547D0BF2Q38176899-F83964C4-CEC4-4945-BCF4-EE942EA16643Q38831521-8347AA0C-2654-41B3-AB97-4694AC445353Q38864839-3DDB0E83-7BBC-444A-A54E-886EA1377617Q40450053-63545029-AF12-4DAA-9B89-D997DC63B9B4
P2860
Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease
@ast
Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease
@en
type
label
Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease
@ast
Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease
@en
prefLabel
Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease
@ast
Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease
@en
P2093
P2860
P356
P1476
Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease
@en
P2093
Oliver Wirths
Sadim Jawhar
Thomas A Bayer
P2860
P304
38825-38832
P356
10.1074/JBC.R111.288308
P407
P577
2011-09-29T00:00:00Z